Eli Lilly, the maker of Wegovy, a weight-loss drug, reported a $16.5 billion deal to boost its supply. The drug Tirzepatide, also by Eli Lilly, has shown potential in reducing blood pressure and treating fatty liver disease. The company's Q4 earnings beat expectations, with adjusted EPS of $2.49 and revenue of $9.35 billion, driven by strong sales of Zepbound, its weight-loss shot, and Mounjaro, its diabetes treatment. The stock surged to a fifth straight record close, leading to a $700 billion valuation. Amgen, another pharmaceutical company, reported Q4 earnings with an EPS of $4.71 and revenue of $8.20 billion, expecting a 20% revenue jump in 2024. CVS Health, on the other hand, beat earnings but lowered its 2024 guidance due to higher medical costs, resulting in a slip in its stock value.
$AMGN (-1.1% pre) Amgen Stock Dipped Despite Beating Fourth-Quarter Sales Forecasts - inv https://t.co/FQ60xWN6tn
$CVS (+1.0% pre) CVS’s stock gains as profit beat offset lowered outlook on higher medical costs - MW https://t.co/RkWePI0WXZ
⚠️ BIG OIL OFFERS RECORD RETURNS TO LURE INVESTORS BACK (Reuters) Big Oil firms are handing shareholders more money than ever and are promising more going forward in an attempt to reassure investors of their discipline and resilience in the face of an uncertain outlook for… https://t.co/os9dEZtCRp
$CVS CEO Karen Lynch on lowered 2024 eps guidance: "we are taking a cautious stance on our outlook for Medicare advantage utilization and we have further clarity of these industrywide trends".. says still aiming for 4%-5% margins in MA in 2025. https://t.co/rSbLzJwdLe
$CVS MLR running hot at 88.5% in q4. Revises 24 guidance for MCR up by 50 bp to 87.7%. Blaming outpatient utilization and Medicare supp benefits including vision and dental. https://t.co/qnRGpkTVTI
CVS’ stock slips after earnings beat by a wide margin but full-year outlook was cut due to higher medical costs https://t.co/waz5DD51Nz
$CVS | CVS Q4 23 Earnings: - Net Rev. $93.81B (est $90.6B) - Adj EPS $2.12 (est $1.98) - Sees 2024 Adj EPS At Least $8.30, Saw At Least $8.50 - Sees 2024 EPS At Least $7.06, Saw At Least $7.26
CVS slashes its 2024 guidance for profit and cash flow from operations as rising medical expenses are expected to hurt its health insurance unit https://t.co/pWCLQ6VnGk
$CVS Due to "potential implications for elevated medical cost trends in 2024" CVS cuts FY guidance. https://t.co/p2JlRDLEEH
$CVS Q4 Adjusted EPS $2.12 beats $1.99 Est. Sales $93.8B beat $90.3B Est. total FY'23 revenues $357.8 Billion.
Eli Lilly on Tuesday said its highly popular drug used for weight loss and diabetes showed promise as a treatment for fatty liver disease in a midstage trial. https://t.co/pYhrdRBBYX
⬇️⬇️⬇️ Wall Street Is Focused on Disney Streaming Profits, Cost Cutting Ahead of Q1 Earnings Earnings preview: The latest quarterly results come as Disney prepares for a showdown with activist investor Nelson Peltz. Read more: https://t.co/tHdTWfiwr4
Shortages of weight-loss drugs are driving pharmaceutical companies to scramble to shore up supplies. Booming demand for anti-obesity drugs, known as GLP-1s, has led to a windfall of revenue for pharma giants like Novo Nordisk and Eli Lilly. https://t.co/7Zaw7jXYgx
The British energy giant BP boosted share repurchases and vowed to make pragmatic investments, in moves to soothe investor concern over its energy transition plans after it posted a forecast-beating earnings of $3 billion in the fourth quarter https://t.co/8N6089TlVY https://t.co/PIhfkk1yu4
Drug companies scramble to boost production of weight-loss drugs https://t.co/CFi4BZ1EHc @NathanBomey
Disney $DIS reports earnings tomorrow after the markets close, Wall ST is expecting numbers of EPS of $1.04 up 5.1% YoY Revenue of $23.77B up 1.1% YoY
CVS Health Earnings Are Soon. The Focus Will Be on the Future of the Medicare Advantage Business. https://t.co/uVT3Bs6SO1
Key Earnings Reports After the Close Tomorrow Disney $DIS Mattel $MAT McKesson $MCK Molina Healthcare $MOH O'Reilly Automotive $ORLY PayPal $PYPL Uber $UBER Waste Connections $WCN Wynn Resorts $WYNN For more details, start a trial at https://t.co/7vJYJeegCP.
Largest stocks that report earnings tomorrow Alibaba $BABA Disney $DIS $UBER CVS Health $CVS Equinor $EQNR Arm Holdings $ARM PayPal $PYPL Mckesson $MCK O'Reilly $ORLY Emerson $EMR Hilton $HLT Suncor $SU Allstate $ALL Yum Brands $YUM $CDW Sun Life $SLF Monolithic Power $MPWR…
Amgen $AMGN expects revenue to jump 20% this year (y/y), beating estimates after acquisition of Hor -Rev $32.4-$33.8bn, est 32.51bn -2024 adj EPS $18.90-20.30, $19.83 -4Q23 $4.71/sh est $4.50 -This was despite a decline in sales of Enbrel
$AMGN | Amgen Q4 Earnings: - EPS $4.71 (Est. $4.62) - Sales $8.20B (Est. $8.13B) - Sees FY24 Revenue $32.4B-$33.8B (Est. $32.66B) - Sees FY24 EPS $18.90-$20.30 (Est. $20.00) https://t.co/5Yvrnps1qr
$AMGN | Amgen Q4 23 Earnings: - Adj EPS $4.71 (est $4.60) - Rev $8.20B (est $8.12B) - Sees 2024 Rev $32.4B To $33.8B (est $32.51B)
Microstrategy, $MSTR earnings: - Revenue: $124.5 million vs $133 million - Says Digital assets now $3.63 billion, up +97% YoY Amgen $AMGN earnings: - EPS $4.71 vs $4.60 - Revenue $8.20 billion vs $8.12 billion Link: https://t.co/Q2LOTrNnz0
$DIS - Here’s another view of the direct Disney vs $NFLX media comp In this update - assumed a reversal to $0 of all F2023 DTC segment losses reported based on the repeatedly confirmed target of 2H-2024 DTC profitability. This only assumes $0, not positive Now have a look $SPY https://t.co/NWJsJQLzPl https://t.co/OTW0IFcI8U
Already rolling in diabetes and obesity, Eli Lilly touts tirzepatide's midstage MASH win https://t.co/MEfVcwCnTz
Eli Lilly rides the weight-loss-drug wave to a new record high and hits a $700 billion valuation https://t.co/mATORdDaMR
Eli Lilly says weight loss drug shows promise as treatment for fatty liver disease https://t.co/rET1QtndLA
Eli Lilly and Co $LLY Earnings: - Diluted EPS of $2.42 (+13% YoY) - Adjusted Diluted EPS of $2.49 (+19% YoY) - Revenue of $9.35 billion (+28% YoY) - Growth Products Revenue of $5.27 billion (+9% YoY) "2023 was a year of tremendous achievement for Lilly, which delivered… https://t.co/a8Taig81ru
Ahead of Disney's earnings report tomorrow, Wall Street is focused on streaming profits and cost cutting. https://t.co/tHdTWfiwr4
$LLY (+4.9% pre) Lilly Reports Strong Fourth-Quarter 2023 Financial Results and Provides 2024 Guidance - PR https://t.co/wIWkiVGL5b
Eli Lilly reports tirzepatide MASH success during Q4 earnings https://t.co/dC0YMwD4AX
$LLY Earnings per share: $2.49 adjusted vs. $2.22 expected Revenue: $9.35 billion vs. $8.93 billion expected Strong launch of its new weight loss drug, Zepbound, and higher prices for its blockbuster diabetes treatment, Mounjaro. https://t.co/fAY2Y7Irtq
The blockbuster weight loss and diabetes drug sold by Eli Lilly also appears to improve fatty liver disease, according to early clinical trial data. https://t.co/waDoZbVl53
that potential NASH benefit --> reality based on today's tirzepatide results from @EliLillyandCo entirely unsurprising: obesity leads to NASH, intervention leads to dramatic weight loss, NASH resolves or stabilizes https://t.co/uBngx9tb9D
$LLY set to open at fresh record. Q4 $2.49 eps V $2.22 on $9.35 B revenues +28%, driven by Diabetes/Weight Loss: - Trulicity $1.67 B - Jardiance $798.1 M - Mounjaro $2.2 B despite "intermittent delays in fulfilling some doses" - Zepbound $175.8 M 👀(it was only approved in Nov) https://t.co/AYaKzU8KiS
Eli Lilly rallies toward a fifth straight record close after earnings beat https://t.co/Rj6wsnBmL5
Eli Lilly’s stock surges toward a 5th straight record after an earnings beat and upbeat outlook https://t.co/5jVMYtEomd
Eli Lilly expects 2024 sales ahead of Wall Street estimates driven by sales of Zepbound, its weight-loss shot https://t.co/DGSrQ6Qx79
[ UPDATED ] COLUMN: Long the paradigm of boom-and-bust cycles, Big Oil is starting to churn rather boring quarterly results. That's great news for shareholders. More in 2024, please: Boring but with lots of cash. #OOTT $XOM $CVX $SHEL $BP | @Opinion https://t.co/d35vLtfkui
BP shares make biggest gains in a year on buyback plan as profit tops estimates https://t.co/9MOQFhpAtD
$BP | BP Q4 23 Earnings: - Adj EPS $17.77 (est $16.27) - Adj Net $2.99B (est $2.76B) - Oper Cash Flow $9.38B (est $8.24B) - Debt Gearing 19.7% (est 19.2%) - Committed To $3.5B Share Buyback For H1 Of 2024 - Announces $1.75B Share Buyback For Q4
Eli Lilly $LLY reports earnings tomorrow before the markets open, Wall ST is expecting numbers of EPS of $2.37 up 13.4% YoY Revenue of $8.97B up 22.9% YoY
Some of the largest stocks that report earnings tomorrow Eli Lilly $LLY Snapchat $SNAP Chipotle $CMG Ford $F Spotify $SPOT Toyota $TM Enphase $ENPH Linde $LIN Amgen $AMGN $BP Gilead $GILD Fiserv $FI $KKR Edwards $EW Fortinet $FTNT Carrier $CARR Centene $CNC Cognizant $CTSH…
A new weight loss drug is also effective at helping lower blood pressure, a study finds. https://t.co/htAZVwVCBI https://t.co/jrjHkQVcz2
Wegovy maker inks $16.5 billion deal to boost weight-loss drug supply https://t.co/sPOnrS6o5p @danprimack
Lilly’s Weight Loss Drug Tirzepatide May Significantly Reduce Blood Pressure, Study Finds https://t.co/s5aQHHjQ6l https://t.co/MLB6gLxwMB
Wegovy maker inks $16.5 billion deal to boost weight-loss drug supply https://t.co/cpnWZLnMq8